Added to YB: 2026-06-30
Pitch date: 2026-06-27
IBRX [bullish]
ImmunityBio, Inc.
+4.9%
current return
Author Info
No bio for this author
Company Info
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Market Cap
$9.1B
Pitch Price
$8.36
Price Target
N/A
Dividend
N/A
EV/EBITDA
-43.55
P/E
-9.82
EV/Sales
69.99
Sector
Biotechnology
Category
growth
The 7 bets on where the world is heading over the next decade. - ImmunityBio, Inc.
IBRX: Immuno-oncology play activating patient's own immune system vs tumors. First drug FDA-approved for bladder cancer, expanding from there. Massive cancer-market upside if it keeps working, but author flags it as riskiest bet—biotech lives & dies on trial results.
Read full article (1 min)